GILBERTSON RYAN RANDALL 4
4 · Sun BioPharma, Inc. · Filed May 29, 2018
Insider Transaction Report
Form 4
GILBERTSON RYAN RANDALL
10% Owner
Transactions
- Conversion
Common Stock
2018-05-16+47,025→ 47,025 total(indirect: Northern Capital Partners I, LP) - Conversion
Convertible Promissory Note
2018-05-16$200000.00/sh−200,000$40,000,000,000→ 0 total(indirect: Northern Capital Partners I, LP)Exercise: $10.10From: 2017-03-17Exp: 2018-12-01→ Common Stock (19,802 underlying) - Conversion
Warrants (right to buy)
2018-05-16+47,025→ 47,025 total(indirect: Northern Capital Partners I, LP)Exercise: $5.00From: 2018-05-16Exp: 2021-05-16→ Common Stock (47,025 underlying)
Holdings
- 555,538
Common Stock
- 28,000(indirect: By Foundation)
Common Stock
Footnotes (3)
- [F1]Pursuant to the "alternate conversion" under the Convertible Promissory Note, approximately $211,616 of outstanding principal and accrued but unpaid interest converted into 47,025 units at a price equal to $4.50 per unit. Each unit consisted of one share of common stock and a warrant to purchase an additional share of common stock.
- [F2]Originally convertible into issuer common stock at a price of $10.10 per share upon holder's election. Because a "qualified offering" occurred, outstanding principal and accrued but unpaid interest would have automatically converted into common stock at a rate of $3.35 per share or, as elected, into units at a rate equal to a 10% discount to the price paid in the qualified offering.
- [F3]Represents original principal amount.